echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Mov Disord: A new type of levodopa intestinal gel, which can effectively slow down the performance of Parkinson’s dyskinesias

    Mov Disord: A new type of levodopa intestinal gel, which can effectively slow down the performance of Parkinson’s dyskinesias

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The combination of levodopa and carbidopa is the mainstream treatment for Parkinson's disease (PD)
    .


    Generally speaking, catechol-O-methyltransferase (COM-T) inhibitors, monoamine oxidase-B (MAO-B) inhibitors and dopamine agonists are used together with levodopa to reduce exercise fluctuations


    Even with the best oral treatment, the management of dyskinesias is often challenging


    Against the background of severe neurodegeneration, unstable absorption, unpredictable changes in gastric emptying and short levodopa half-life, multiple oral doses of levodopa can lead to instability of plasma levodopa levels.
    Therefore, the basal The level of dopamine in the ganglia is also unstable
    .

    Therefore, the level of dopamine in the basal ganglia is also unstable
    .


    Therefore, the dyskinesia of PD may come from drug treatment, especially levodopa treatment
    .


    Treatment options for movement disorders include oral amantadine, continuous subcutaneous apomorphine infusion, and deep brain stimulation (DBS)


    Levodopa-Carbidopa Intestinal Gel (LCIG) is continuously delivered to the upper intestine through percutaneous endoscopic gastrostomy and J tube extension (PEG-J) using an external pump
    .


    Compared with standard oral levodopa therapy, LCIG provides more stable plasma levels of levodopa, thereby reducing the possibility of motor complications and dyskinesias


    However, these studies use the patient’s PD diary and/or the exercise part (Part 4) of the Unified Rating Scale for Parkinson’s Disease (UPDRS) to assess dyskinesias, the sensitivity of these two methods to changes and the ability to quantify dyskinesia symptoms All are very limited
    .

    Unified Dyskinesia Rating Scale (UDysRS) was developed to assess the patient "on" dyskinesias and "off" muscle tension historic disability barriers, an objective evaluation of the severity and distribution of motion disorders, movement disorders and provide some measure Metric attributes of each aspect
    .


    There are currently no randomized clinical trials to compare the effectiveness of LCIG for dyskinesias with optimized treatment (OMT) using UdysRS


    tension

    In this way, Eric Freire-Alvarez of the University General Hospital of Elche, Spain, and others conducted a 12-week randomized study in patients with advanced Parkinson’s disease to evaluate LCIG and OMT in dyskinesias through UdysRS and Parkinson’s disease diary.
    Effectiveness in terms of symptoms
    .

    In addition, they also compared the differences between LCIG and OMT in exercise fluctuations, health-related outcomes, safety and tolerability
    .

    In addition, they also compared the differences between LCIG and OMT in exercise fluctuations, health-related outcomes, safety and tolerability
    .


    In this phase 3b, open-label, multicenter, 12-week intervention study (NCT02799381), 63 patients with advanced PD who did not receive LCIG treatment (UDysRS≥30) were randomly assigned to LCIG (N = 30) or OMT ( N = 33) Treatment
    .


    The effect of dyskinesia was assessed using UdysRS from baseline to week 12


    After 12 weeks, compared with the OMT group (n = 26; -2.
    33 ± 2.
    56), the LCIG group (n = 24; -17.
    37 ± 2.
    79) had significantly less dyskinesia measured by UdysRS (-15.
    05 ± 3.
    20; 95% CI,- 21.
    47 to -8.
    63; P <0.
    0001)
    .

    In the 12th week, compared with OMT, LCIG had no troublesome dyskinesias in the "remaining" time (P = 0.
    0001), QoL (P <0.
    0001), global change impression (P <0.
    0001), activities of daily living (P = 0.
    0006) and the third part of the Unified Parkinson’s Disease Score (UPDRS) (P = 0.
    0762)
    .

    Twenty-seven (44.
    3%) patients reported adverse events during treatment (LCIG, 18[64.
    3%]; OMT, 9[27.
    3%])
    .


    Serious adverse events occurred in 2 patients (7.


    Compared with OMT, LCIG significantly reduces the occurrence of dyskinesias
    .


    LCIG has shown efficacy in the treatment of troublesome dyskinesias in patients with advanced PD, and has shown benefits in both motor and non-motor symptoms and QoL
    .

    Compared with OMT, LCIG significantly reduces the occurrence of dyskinesias
    .

    Original source:
    Freire-Alvarez E, Kurča E, Lopez Manzanares L, et al.
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord.
    Published online July 8, 2021:mds.
    28703.
    doi:10.
    1002 /mds.
    28703


    Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.